

JENKINS
WILSON
& TAYLOR

patent attorney

August 17, 2004



JFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 17, 2004.

Cathi H. Turner

Date of Signature: August 17, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/785,374 for
THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE
PRECURSORS
Our Ref. No. 1242/58

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (7 pages) in duplicate;
3. Copies of cited references (49 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.


Arles A. Taylor, Jr.
Registration No. 39,395

AAT/ptw/cht
Enclosures
Customer No: 25297

tel 919.493.8000
fax 919.419.0383

Jenkins, Wilson & Taylor, P.A.
JenkinsWilsonTaylor.com

University Tower, Suite 1400 | 3100 Tower Boulevard | Durham, North Carolina 27707



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 17, 2004.

Cathi H. Turner
Cathi H. Turner
Date of Signature August 17, 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Summar et al.

Group Art Unit: 1638

Serial No.: 10/785,374

Examiner: Unknown

Filed: February 24, 2004

Docket No.: 1242/58

Confirmation No.: 1629

For: THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE PRECURSORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Copies of the cited documents 49-58 are of record in the file history of U.S. Patent Application Serial No. 09/585,077 filed on June 1, 2000 (now U.S. Patent No.

Serial No.: 10/785,374

6,743,823). Copies of the cited documents 59-62 are of record in the file history of U.S. Patent Application No. 09/323,472 filed June 1, 1999 (now U.S. Patent No. 6,346,382). The above-captioned application claims priority to U.S. Patent 6,743,823 and U.S. Patent No. 6,346,382 under 35 U.S.C. § 120, and as per 37 C.F.R. § 1.98, no copies of these cited documents are believed to be required.


Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 08/17/2004

By: 
Arles A. Taylor, Jr.
Registration No. 39,395

AAT/ptw/cht

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

List of Documents Cited by Applicant



Attorney Docket No.:	1242/58
Serial No.:	10/785,374
Filing Date:	February 24, 2004
First Named Inventor:	Summar et al.
Examiner:	
Group:	

U.S. PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Name	Relevant pages
	1.	5,874,471	2/23/1999	Waugh	
	2.	5,891,459	4/6/1999	Cooke et al.	
	3.	6,337,321 B1	1/8/2002	Cooke et al.	
	4.	US 2002/0013288 A1	1/31/2002	Cooke et al.	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	5.	Pearson et al. "Neonatal Pulmonary Hypertension," <u>N Engl J Med</u> , 344(24) : 1832-1838. (June 12 2001).
	6.	Gebhardt et al. "Treatment of Cirrhotic Rats with L-Ornithine-L-Aspartate Enhances Urea Synthesis and Lowers Serum Ammonia Levels," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283(1) : 1-6 (1997).
	7.	Kurowka, "Nitric Oxide Therapies in Vascular Diseases," <u>Current Pharmaceutical Design</u> , 8 : 155-166 (2002).
	8.	Morrow, "The Isoprostanes: Their Quantification as an Index of Oxidant Stress Status in Vivo," <u>Drug Metabolism Reviews</u> , 32(3&4) : 377-385 (2000).

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	9.	Suzuki et al. "Effect of Local Delivery of L-Arginine on In-stent Restenosis in Humans," <u>The American Journal Of Cardiology</u> , 89 : 363-367 (February 15, 2002).	
	10.	Benedetto et al. "Increased L-citrulline/L-arginine plasma ratio in severe preclampsia," <u>Obstet Gynecol</u> , 96(3) : 395-399 (September 2000). (ABSTRACT)	
	11.	Baumgartner et al. "Hyperammonemia with reduced ornithine, arginine and praline: a new inborn error caused by a mutation in the gene encoding delta(1)-pyrroline-5-carboxylate synthase," <u>Hum Mol Genet</u> , 9(19) : 2853-2858 (November 22, 2000). (ABSTRACT)	
	12.	Chwalisz et al. "Role of nitric oxide in implantation and menstruation," <u>Hum Reprod</u> , 15(suppl 3) : 96-111 (August 2000). (ABSTRACT)	
	13.	Mori et al. "Regulation of nitric oxide production by arginine metabolic enzymes," <u>Biochem Biophys Res Commun</u> , 275(3) : 715-719 (September 7 2000). (ABSTRACT)	
	14.	Muriel, "Regulation of nitric oxide synthesis in the liver," <u>J Appl Toxicol</u> , 20(3) : 189-195 (May-June 2000). (ABSTRACT)	
	15.	Bredt, "Endogenous nitric oxide synthesis: biological functions and pathophysiology," <u>Free Radic Res</u> , 31(6) : 577-596 (December 1999). (ABSTRACT)	
	16.	Akashi et al. "Citrulline, a novel compatible solute in drought-tolerant wild watermelon leaves, is an efficient hydroxyl radical scavenger," <u>FEBS Lett</u> , 508(3) : 438-442 (November 23 2001). (ABSTRACT)	
	17.	Ikeda et al. "Cardiovascular effects of citrulline in ischemia/ reperfusion injury via a non-nitric oxide-mediated mechanism," <u>Methods Find Exp Clin Pharmacol</u> , 22(7) : 563-571 (September 2000). (ABSTRACT)	
	18.	Stuhlinger et al. "Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor," <u>JAMA</u> , 287(11) : 1420-1426 (March 20, 2002). (ABSTRACT)	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	19.	Stuhlinger et al. "Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine," <u>Circulation</u> , 104(21) : 2569-2575 (November 20, 2001). (ABSTRACT)	
	20.	Dulak et al. "Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells," <u>Arterioscler Thromb Vasc</u> , 20(3) : 659-666 (March 2000). (ABSTRACT)	
	21.	Cooke, "Does ADMA cause endothelial dysfunction?" <u>Arterioscler Thromb Vasc Biol</u> , 20(9) : 2032-2037 (September 2000). (ABSTRACT)	
	22.	Cooke et al. "Atherogenesis and the arginine hypothesis," <u>Curr Atheroscler Rep</u> , 3(3) : 252-259 (May 2001). (ABSTRACT)	
	23.	Cooke, "The endothelium: a new target for therapy," <u>Vasc Med</u> , 5(1) : 49-53 (2000). (ABSTRACT)	
	24.	Boger et al. "An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes," <u>J Am Cardiol</u> , 36(7) : 2287-2295 (December 2000). (ABSTRACT)	
	25.	Boger et al. "Is asymmetric dimethylarginine a novel mark of atherosclerosis?" <u>Circulation</u> , 101(14) : 160-161 (April 11, 2000). (ABSTRACT)	
	26.	Uemura et al. "Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia," 102(21) : 2629-2635 (November 21, 2000). (ABSTRACT)	
	27.	Jang et al. "Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine," <u>Circulation</u> , 102(12) : 1414-1419 (September 19 2000). (ABSTRACT)	
	28.	Lundman et al. "Mild-to-moderate hypertriglycerida in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine," <u>J Am Coll Cardiol</u> , 38(1) : 111-116 (July 2001). (ABSTRACT)	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
List of Documents Cited by Applicant		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	29.	Maxwell et al. "Endothelial dysfunction in hypercholesterolemia is reserved by a nutritional product designed to enhance nitric oxide activity," <u>Cardiovasc Drugs Ther</u> , 14(3) : 309-316 (June 2000). (ABSTRACT)	
	30.	Chan et al. "Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans," <u>Arterioscler Thromb Vasc Biol</u> , 20(4) : 1040-1046 (April 2000). (ABSTRACT)	
	31.	Maxwell et al. "L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production," <u>J Appl Physiol</u> , 90(3) : 933-938 (March 2001). (ABSTRACT)	
	32.	Maxwell et al. "Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar," <u>Vasc Med</u> , 5(1) : 11-19 (2000). (ABSTRACT).	
	33.	Schwarzacher et al. "effects of stenting on adjacent vascular distensibility and neointima formation: role of nitric oxide," <u>Vasc Med</u> , 6(3) : 139-144 (2001). (ABSTRACT)	
	34.	Schwarzacher et al "Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty," <u>Circulation</u> , 95(7) : 1863-1869 (April 1, 1997). (ABSTRACT)	
	35.	Niebauer et al. "Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis," <u>Circulation</u> , 100(17) : 1830-1835 (October 26, 1999). (ABSTRACT)	
	36.	Niebauer et al. "Gene transfer of nitric oxide synthase: effects on endothelial biology," <u>J Am Coll Cardiol</u> , 34(4) : 1201-1207 (October 1999). (ABSTRACT)	
	37.	Kurowska, "Nitric oxide therapies in vascular diseases," <u>Curr Pharm Des</u> , 8(3) : 155-166 (2002). (ABSTRACT)	
	38.	Vosatka, "Persistent pulmonary hypertension of the newborn," <u>N Engl J Med</u> , 346(11) : 864 (March 14, 2002). (ABSTRACT)	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	39.	Waugh et al. "Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results," <u>J Natl Med Assoc</u> , 93(10) : 363-371 (October 2001). (ABSTRACT)	
	40.	O'Connor et al. "Nonalcoholic fatty liver (NASH syndrome)," <u>Gastroenterologist</u> , 5(4) : 316-329 (December 1997). (ABSTRACT)	
	41.	Bruno et al. "Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel," <u>Invest New Drugs</u> , 19(2) : 163-169 (May 2001). (ABSTRACT)	
	42.	Gur et al. "Determination of hepatic zinc content in chronic liver sdisease due to hepatitis Bv virus," <u>Hepatogastroenterology</u> , 45(20) : 472-476 (March-April 1998). (ABSTRACT)	
	43.	Durand et al. "Acute liver failure in infancy: a 14-year experience of a pediatric liver transplantation center," <u>J Pediatr</u> , 139(6) : 871-876 (December 2000). (ABSTRACT)	
	44.	Maier et al "Activities of urea-cycle enzymes in chronic liver disease," <u>Klin Wochenschr</u> , 57(13) : 661-665 (July 3, 1979). (ABSTRACT)	
	45.	Cohen et al. "The SGOT/SGPT ratio--an indicator of alcoholic liver disease," <u>Dig Dis Sci</u> , 24(11) : 835-838 (November 1979). (ABSTRACT)	
	46.	Alves et al. "The SGOT/SGPT rataio in alcoholic liver disease," 3(4) : 255-260 (July-August 1981). (ABSTRACT)	
	47.	Treem et al. "Disorders of the mitochondria," <u>Semin Liver Dis</u> , 18(3) : 237-253 (1998). (ABSTRACT)	
	48.	Fearon et al., "Genetic Analysis of Carbamyl Phosphate Synthetase I Deficiency," <u>Human Genetics</u> , Vol. 70, No. 3, pp. 207-210 (1985).	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	49.	Finckh et al., "Prenatal Diagnosis of Carbamoyl Phosphate Synthetase I Deficiency by Identification of a Missense Mutation in CPS1," <u>Human Mutation</u> , Wiley-Liss, NY, Vol. 12, No. 3, pp. 206-211 (1998).	
	50.	Ghishan et al., "Polymerase Chain Reaction (PCR) Detectable Polymorphisms in the Prenatal Diagnosis of Carbamyl Phosphate Synthetase I Deficiency," <u>Gastroenterology</u> , Vol. 106, No. 4 Suppl., p. A1028 (1994).	
	51.	Haraguchi et al., "Cloning and Sequence of a cDNA Encoding Human Carbamyl Phosphate Synthetase I Molecular Analysis of Hyperammonemia," <u>Gene</u> , Vol. 107, No. 2, pp. 335-340 (1991).	
	52.	Vnencak-Jones et al., "Efficacy of Prenatal DNA Testing for Carbamyl Phosphate Synthetase I Deficiency," <u>Am. Jour. Human Genetics</u> , Vol. 51, No. 4 Suppl., p. A357 (1992).	
	53.	Alonso et al., "Affinity Cleavage of Carbomoyl-Phosphate Synthetase I Localizes Regions of the Enzyme Interacting with the Molecule of ATP that Phosphorylates Carbamate," <u>Eur. J. Biochem</u> , p. 377-384, (1995).	
	54.	Guillou et al., "Escherichia Coli Carbamoyl-Phosphate Synthetase: Domains of Glutaminase and Synthetase Subunit Interaction," <u>Proc. Natl. Acad. Sci. USA</u> , p. 8304-8308, (November 14, 1989).	
	55.	Guy et al., "Substructure of the Amidotransferase Domain of Mammalian Carbamyl Phosphate Synthetase," <u>J. Biol. Chem</u> , Vol. 270 (No. 5), p. 2190-2197, (February 3, 1995).	
	56.	Lagace et al., "Rat Carbamyl-Phosphate Synthetase I Gene," <u>J. Biol. Chem</u> , Vol. 262 (No. 22), p. 10415-10418, (August 5, 1987).	
	57.	Nyunoya et al., "Characterization and Derivation of the Gene Coding for Mitochondrial Carbamyl Phosphate Synthetase I of Rat," <u>J. Biol. Chem.</u> , Vol. 260 (No. 16), p. 9346-9356, (August 5, 1985).	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	58.	Mize, et al., "Urea Cycle Disorders" Mol. Genet. Basis. Neurol. Dis., 2 nd ed., 1151-1174 (1997).	
	59.	Hoshide et al., J. Clin. Invest. Vol. 91(5), p. 1884-1887 (May 1993).	
	60.	Erlich et al., Science Vol. 252:1143-1151 (June 1991).	
	61.	MacCallum, "Detection of PCR Amplified Products" PCR Essential Data, p. 99-127 (1995).	

EXAMINER _____

DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.